Avastin (bevacizumab) - 400mg - For Intravenous Use
date: label: date made
content: ca 2013
label: product expiration date
content: 2014-10
name: label: maker
content: Genentech, Inc.
notes: label: Description (Brief)
content: (From box) For Intravenous Use
label: Description (Brief)
content: (From insert)
label: Description (Brief)
content: Metastatic Colorectal Cancer (mCRC) Avastin is indicated for the first- or second-line treatment of patients with metastatic carcinoma of the colon or rectum in combination with intravenous 5-flurouracil-based chemotherapy.
label: Description (Brief)
content: Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Avastin is indicated for the first-line treatment of unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer in combination with carboplatin and paclitaxel.
label: Description (Brief)
content: Glioblastoma Avastin is indicated for the treatment of glioblastoma with progressive disease in adult patients following prior therapy as a single agent. The effectiveness of Avastin in glioblastoma is based on an improvement in objective response rate. There are no data demonstrating an improvement in disease-related symptoms or increased survival with Avastin.
label: Description (Brief)
content: Metastatic Renal Cell Carcinoma (mRCC) Avastin is indicated for the treatment of metastatic renal cell carcinoma in combination with interferon alfa.
label: Location
content: Currently not on view
place: label: place made
content: United States: California, South San Francisco
setName: label: See more items in
content: Medicine and Science: Medicine
label: See more items in
content: Health & Medicine
label: See more items in
content: The Antibody Initiative
label: See more items in
content: Cancer
label: See more items in
content: Antibody Initiative: Monoclonal Antibodies
label: See more items in
content: Cancer: Treatment
creditLine: label: Credit Line
content: Gift of Genentech, Inc.
dataSource: label: Data Source
content: National Museum of American History
identifier: label: ID Number
content: 2013.0069.02
label: catalog number
content: 2013.0069.02
label: accession number
content: 2013.0069
label: maker number
content: 510569
objectType: label: Object Name
content: pharmaceutical
label: Object Name
content: biological
physicalDescription: label: Physical Description
content: metal (overall material)
label: Physical Description
content: plastic (overall material)
label: Physical Description
content: glass (overall material)
label: Physical Description
content: cardboard (overall material)
label: Physical Description
content: bevacizumab, 400 mg (20mg/mL) (overall ingredient)
label: Measurements
content: overall: 1 1/2 in x 2 3/4 in x 5 1/4 in; 3.81 cm x 6.985 cm x 13.335 cm
label: Measurements
content: avastin bottle: 2 1/2 in x 1 1/4 in; 6.35 cm x 3.175 cm
label: Measurements
content: overall: 5 1/4 in x 2 3/4 in x 1 1/2 in; 13.335 cm x 6.985 cm x 3.81 cm